William P Tansey

List of Publications by Year
in descending order

55 papers	5,036 citations	172457 29 h-index	161849 54 g-index
57 all docs	57 docs citations	57 times ranked	5470 citing authors

#	Article	IF	Citations
1	How the ubiquitinâ€“proteasome system controls transcription. Nature Reviews Molecular Cell Biology, 2003, 4, 192-201.	37.0	725
2	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature, 2005, 436, 807-811.	27.8	419
3	Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO Journal, 1999, 18, 717-726.	7.8	394
4	Regulation of Transcriptional Activation Domain Function by Ubiquitin. Science, 2001, 293, 1651-1653.	12.6	346
5	Ubiquitin and Proteasomes in Transcription. Annual Review of Biochemistry, 2012, 81, 177-201.	11.1	256
6	Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3118-3123.	7.1	248
7	The proteasome: a utility tool for transcription?. Current Opinion in Genetics and Development, 2006, 16, 197-202.	3.3	234
8	Interaction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYC. Molecular Cell, 2015, 58, 440-452.	9.7	224
9	Proteasomal ATPases Link Ubiquitylation of Histone H2B to Methylation of Histone H3. Molecular Cell, 2004, 13, 435-442.	9.7	186
10	Mammalian MYC Proteins and Cancer. New Journal of Science, 2014, 2014, 1-27.	1.0	170
11	The Proteasome Regulatory Particle Alters the SAGA Coactivator to Enhance Its Interactions with Transcriptional Activators. Cell, 2005, 123, 423-436.	28.9	165
12	The F Box Protein Dsg1/Mdm30 Is a Transcriptional Coactivator that Stimulates Gal4 Turnover and Cotranscriptional mRNA Processing. Cell, 2005, 120, 887-899.	28.9	155
13	Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3118-3123.	7.1	135
14	Myc-Mediated Transcriptional Repression by Recruitment of Histone Deacetylase. Cancer Research, 2008, 68, 3624-3629.	0.9	96
15	Moonlighting with WDR5: A Cellular Multitasker. Journal of Clinical Medicine, 2018, 7, 21.	2.4	94
16	A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Reports, 2005, 6, 177-183.	4.5	88
17	Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity. Cell Reports, 2019, 26, 2916-2928.e13.	6.4	70
18	Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25260-25268.	7.1	69

#	Article	IF	Citations
19	Damage control: DNA repair, transcription, and the ubiquitinâ€"proteasome system. DNA Repair, 2009, 8, 444-448.	2.8	57
20	Inhibition of MYC by the SMARCB1 tumor suppressor. Nature Communications, 2019, 10, 2014.	12.8	57
21	Modulation of RNA polymerase II subunit composition by ubiquitylation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19649-19654.	7.1	54
22	Discovery of Potent 2-Aryl-6,7-dihydro-5<i>H</i>-pyrrolo[1,2-<i>a</i>]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design. Journal of Medicinal Chemistry, 2018, 61, 5623-5642.	6.4	54
23	The MYCâ€"WDR5 Nexus and Cancer. Cancer Research, 2015, 75, 4012-4015.	0.9	52
24	Combined chemical and genetic approach to inhibit proteolysis by the proteasome. Yeast, 2010, 27, 965-974.	1.7	51
25	Similar temporal and spatial recruitment of native 19S and 20S proteasome subunits to transcriptionally active chromatin. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6060-6065.	7.1	49
26	Discovery of WD Repeat-Containing Protein 5 (WDR5)â€"MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design. Journal of Medicinal Chemistry, 2020, 63, 4315-4333.	6.4	47
27	MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factorâ€"1. ELife, 2021, 10, .	6.0	45
28	Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5â€"MYC Proteinâ€"Protein Interaction. Journal of Medicinal Chemistry, 2019, 62, 11232-11259.	6.4	40
29	WDR5 is a conserved regulator of protein synthesis gene expression. Nucleic Acids Research, 2020, 48, 2924-2941.	14.5	40
30	Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. Journal of Medicinal Chemistry, 2020, 63, 656-675.	6.4	33
31	Functions of the Proteasome on Chromatin. Biomolecules, 2014, 4, 1026-1044.	4.0	31
32	Adenovirus E1A targets p400 to induce the cellular oncoprotein Myc. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 6103-6108.	7.1	30
33	Impact of WIN site inhibitor on the WDR5 interactome. Cell Reports, 2021, 34, 108636.	6.4	29
34	Interaction of MYC with host cell factor-1 is mediated by the evolutionarily conserved Myc box IV motif. Oncogene, 2016, 35, 3613-3618.	5.9	28
35	Gal4 turnover and transcription activation. Nature, 2009, 461, E7-E7.	27.8	27
36	A common functional consequence of tumor-derived mutations within c-MYC. Oncogene, 2015, 34, 2406-2409.	5.9	27

#	Article	IF	Citations
37	Targeting WDR5: A WINning Anti-Cancer Strategy?. Epigenetics Insights, 2019, 12, 251686571986528.	2.0	25
38	Drugging the â€œUndruggableâ€•MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. Cancer Research, 2021, 81, 1627-1632.	0.9	25
39	Targeting MYC through WDR5. Molecular and Cellular Oncology, 2020, 7, 1709388.	0.7	24
40	Proteolytic Instability and the Action of Nonclassical Transcriptional Activators. Current Biology, 2010, 20, 868-871.	3.9	22
41	Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization. Journal of Medicinal Chemistry, 2022, 65, 6287-6312.	6.4	15
42	Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler. Oncogene, 2021, 40, 3593-3609.	5.9	14
43	Histone H2B ubiquitylation and H3 lysine 4 methylation prevent ectopic silencing of euchromatic loci important for the cellular response to heat. Molecular Biology of the Cell, 2011, 22, 2741-2753.	2.1	13
44	The ubiquitin-selective chaperone Cdc48/p97 associates with Ubx3 to modulate monoubiquitylation of histone H2B. Nucleic Acids Research, 2014, 42, 10975-10986.	14.5	13
45	Phosphorylation of XIAP at threonine 180 controls its activity in Wnt signaling. Journal of Cell Science, 2018, 131, .	2.0	11
46	WIN site inhibition disrupts a subset of WDR5 function. Scientific Reports, 2022, 12, 1848.	3.3	10
47	Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells. NAR Cancer, 2022, 4, zcac007.	3.1	8
48	Letter to the Editor. Yeast, 2012, 29, 93-94.	1.7	7
49	Antagonistic roles for the ubiquitin ligase Asr1 and the ubiquitin-specific protease Ubp3 in subtelomeric gene silencing. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1309-1314.	7.1	6
50	The SWI/SNF ATPase BRG1 facilitates multiple pro-tumorigenic gene expression programs in SMARCB1-deficient cancer cells. Oncogenesis, 2022, 11, .	4.9	5
51	Interaction of Gcn4 with target gene chromatin is modulated by proteasome function. Molecular Biology of the Cell, 2016, 27, 2735-2741.	2.1	4
52	MYC and Chromatin. Open Access Journal of Science and Technology, 2015, 3, .	0.2	4
53	Elevating SOX2 Downregulates MYC through a SOX2:MYC Signaling Axis and Induces a Slowly Cycling Proliferative State in Human Tumor Cells. Cancers, 2022, 14, 1946.	3.7	4
54	Gene-specific quantification of nascent transcription following targeted degradation of endogenous proteins in cultured cells. STAR Protocols, 2021, 2, 101000.	1.2	1

#	Article	IF	Citations
55	Do changes in the c-MYC coding sequence contribute to tumorigenesis?. Molecular and Cellular Oncology, 2015, 2, e965631.	0.7	0